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ABSTRACT
Designer nucleases have been successfully em-
ployed to modify the genomes of various model or-
ganisms and human cell types. While the specificity
of zinc-finger nucleases (ZFNs) and RNA-guided en-
donucleases has been assessed to some extent, lit-
tle data are available for transcription activator-like
effector-based nucleases (TALENs). Here, we have
engineered TALEN pairs targeting three human loci
(CCR5, AAVS1 and IL2RG) and performed a detailed
analysis of their activity, toxicity and specificity. The
TALENs showed comparable activity to benchmark
ZFNs, with allelic gene disruption frequencies of 15–
30% in human cells. Notably, TALEN expression was
overall marked by a low cytotoxicity and the absence
of cell cycle aberrations. Bioinformatics-based analy-
sis of designer nuclease specificity confirmed partly
substantial off-target activity of ZFNs targeting CCR5
and AAVS1 at six known and five novel sites, respec-
tively. In contrast, only marginal off-target cleavage
activity was detected at four out of 49 predicted off-
target sites for CCR5- and AAVS1-specific TALENs.
The rational design of a CCR5-specific TALEN pair
decreased off-target activity at the closely related
CCR2 locus considerably, consistent with fewer ge-
nomic rearrangements between the two loci. In con-
clusion, our results link nuclease-associated toxicity
to off-target cleavage activity and corroborate TAL-
ENs as a highly specific platform for future clinical
translation.
INTRODUCTION
Dimeric designer nucleases, such as zinc-finger nucleases
(ZFNs) and transcription activator-like effector nucleases
(TALENs), have become increasingly popular for targeted
genome modification in the last decade (1–3). From the
pioneering studies of Kim et al. in 1996 (4), significant
advancements in the design process of ZFNs and TAL-
ENs and a better understanding of parameters determin-
ing their activity and toxicity (5,6) have propelled the use
of these nucleases from reverse genetics studies in model
organisms to their application in human gene therapy (7).
These protein-based nucleases are composed of specific
DNA binding domains that direct the non-specific FokI en-
donuclease domain to a predetermined target site (8,9). The
resulting DNA double strand break (DSB) can be harnessed
to introduce permanent genetic modification by activating
one of the two major cellular DSB repair pathways, non-
homologous end joining (NHEJ) or homology-directed
repair (1). While ZFNs represent the best-characterized
class of designer nucleases today, their widespread use has
somewhat been hampered by their limited targeting range
and the time-consuming methodologies needed to generate
ZFNs with novel DNA binding properties (2). TALENs, on
the other hand, are easier to engineer and seem to combine
high cleavage activity with low cytotoxicity, features that
have promoted TALENs as a powerful genome engineering
tool in the last two years (3).
The modular DNA recognition domain of transcription
activator-like effectors (TALEs) was originally found in nat-
ural transcription factors encoded by pathogenic bacteria of
the genus Xanthomonas (10,11) and more recently in Ralsto-
nia solanacearum (12). Xanthomonas TALEs are the most
widely used in the genome engineering field. Each module
within their DNA binding domain consists of a conserved
stretch of typically 34 residues that mediates the interac-
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tion with a single nucleotide via a di-residue in positions
12 and 13, called the ‘repeat variable di-residues’ (RVDs)
(10,11). Modules with different specificities can be fused
into tailored arrays without the context-dependency issues
that represent the major limitation for the generation of
zinc-finger arrays. Hence, this simple ‘one module to one
nucleotide’ cypher makes the generation of TALENs with
novel specificities rapid and affordable (13,14).
A compelling alternative to ZFNs and TALENs are
RNA-guided endonucleases (RGNs) that have quickly de-
veloped into an easy and versatile tool for genome engineer-
ing (15). They are based on natural RGNs used by bacteria
and archaea as a defense system against invading exogenous
DNA and consist of the Cas9 cleavage enzyme complexed
to a guide RNA (gRNA) strand that directs the enzyme to a
∼20 nt long target site (16). Exchanging specific portions of
the gRNA molecule allows scientists to re-direct the Cas9
cleavage activity to user-defined sequences (17).
All of the above described designer nuclease platforms
have shown great potential for genome surgery in complex
organisms and have been employed with remarkable success
to modify genes in a variety of species (1,3,15), including
human stem cells (18–23). Notably, ZFNs have been suc-
cessfully applied in clinical trials for the ex vivo modification
of patient derived CD4+ T cells to generate transplantable
HIV-resistant cells by specific disruption of the viral co-
receptor CCR5 (7,24,25). On the other hand, genome-wide
assessment of the specificity of the ZFNs employed in these
studies revealed a non-trivial degree of off-target cleavage
(26,27). Similarly, RGNs have shown high frequency of off-
target mutagenesis that, at least in its current form, may
hamper their use in therapeutic applications (28–32). A
few studies have reported that TALENs can be generated
with similar activities as ZFNs (33–36). Moreover, TAL-
ENs seem to be better tolerated both in human cell lines and
rats (36,37); however, whether ‘better tolerability’ correlates
with higher specificity and/or lower off-target cleavage ac-
tivity has not been addressed in detail yet. High-throughput
methods that have been used to profile off-target activi-
ties of ZFNs (26,27) and TALENs (38) are either not ro-
bust enough or technically too complex to be routinely used
to assess designer nuclease related off-target cleavage ac-
tivity. Importantly, the published reports have shown that
ZFN and RGN-driven off-target cleavage is largely based
on sequence identity to the intended target site. Consider-
ing that context-dependent effects between the repeat units
have not been reported for TALE-based DNA binding do-
mains, it is reasonable to assume that TALEN binding to
off-target sites also depends on sequence identity. Because
of the lack of a biological assay, bioinformatics prediction
is the only available system to predict potential off-target
cleavage sites of TALENs. Given the potential of TALEN-
mediated genome engineering in a therapeutic context, a
more exhaustive analysis to relate nuclease-associated activ-
ity and toxicity with nuclease specificity is highly warranted.
Here, we have characterized the activity and toxicity of
TALENs targeted to three different human loci. We show
that our optimized TALEN scaffold (36) enables the gen-
eration of functional nuclease pairs that match the activity
set by benchmark ZFNs. Importantly, our study revealed
that TALEN expression in cell lines is associated with a low
cytotoxicity. This observation was consistent with the ab-
sence of cell cycle aberrations and few genomic rearrange-
ments as assessed at the CCR2/CCR5 loci. Moreover, our
results suggest that the benign cytotoxicity profile is due to
a high specificity of TALENs, as evident from the low level
of cleavage activity at predicted off-target sites. Hence, our
data link low cytotoxicity to high specificity and establish




Target sites at the three chosen human loci where identi-
fied in proximity of benchmark ZFN targets without using
previously published algorithms. TALE-based DNA bind-
ing domains were assembled using a previously described
Golden Gate assembly kit (39) that was modified with four
different Level 3 destination vectors to express functional
nuclease monomers based on our previously optimized
TALEN scaffold (36) (135/+17; Supplementary Figure
S1). These vectors included the 17.5th repeat and the wild-
type FokI cleavage domain (pVAX CMV TALshuttle(xx);
‘xx’ stands for the four different 17.5th RVDs used, NI, NG,
HD and NN). The ZFN expression plasmids were gener-
ated by subcloning previously published zinc-finger arrays
(codon-optimized and synthesized by GeneArt/Life Tech-
nologies, Regensburg) into the pRK5.N backbone (40),
which includes an N-terminal HA tag and the SV40 nu-
clear localization domain and either of the obligate het-
erodimeric FokI variant KV or EA (41) at the C-terminus.
Amino acid sequences of the used ZFNs and TALENs
are indicated in Supplementary Figure S1. The toxic ZFN
(GZF1N/GZF3N) (40) was included as a positive control.
Cell culture and transfection
HEK293T and HeLa FUCCI cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM, PAA) supple-
mented with 10% Fetal Bovine Serum (FBS, PAA), 100
U/ml penicillin (PAA) and 100 g/ml streptomycin (PAA).
K562 cells were cultured in RPMI1640 media (Invitrogen)
supplemented with 10% FBS, 100 U/ml penicillin and 100
g/ml streptomycin, 2 mM L-glutamine (PAA). Primary
human newborn foreskin fibroblasts (NuFFs) were main-
tained in low-glucose DMEM supplemented with 10% FBS,
100 U/ml penicillin and 100 g/ml streptomycin, 2 mM
L-glutamine and 1% Na-pyruvate (PAA). HEK293T and
HeLa FUCCI cells were transfected using polyethylenimin
(PEI), as described before (36). NuFF and K562 cells were
nucleofected using the NHDF or V kit (Lonza) and pro-
grams U-023 and T-016, respectively, following the manu-
facturer instructions.
Gene disruption
HEK293T and NuFF cells were transfected with 400 ng or
1.25 g of each nuclease expression plasmid and pUC118
to normalize for DNA amount, harvested at the indicated
time points to extract DNA using QIAamp DNA mini kit
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(Qiagen), the target loci amplified by polymerase chain re-
action (PCR; see Supplementary Table S7 for primers), and
then the extent of gene disruption assayed by T7 endonucle-
ase 1 (T7E1, New England Biolabs) as previously described
(36). For analysis under hypothermic conditions, cells were
shifted to 30◦ for 3 days 4 h after transfection.
Nuclease expression
HEK293T cells were PEI transfected, as described above,
and harvested at indicated time points. Protein lysates
were prepared using RIPA buffer (50 mM Tris, 150
mM NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycholate).
ZFNs/TALENs or -actin were detected using anti-HA
tag (1:2000; Novus Biologicals) or anti--actin (1:2000;
Cell Signaling) antibodies, respectively. Detection was per-
formed using Horseradish Peroxidase (HRP)-conjugated
anti-rabbit antibody (Dianova) and West Pico chemilumi-
nescence substrate (Thermo Scientific).
Gene expression
Total RNA was extracted from 1 × 106 cells (HEK293T,
NuFF or K562) using the TRIzol Reagent (Life Tech-
nologies) and reverse-transcribed with QuantiTect Reverse
Transcription Kit (Qiagen). RT-PCR amplicons of CCR5,
AAVS1, IL2RG and GAPDH loci were generated with
primers listed in Supplementary Table S7 using program [1
min at 95◦; 30 cycles of 95◦ for 5 s, 60◦ for 10 s and 72◦ for 7
s; 1 min at 72◦] and resolved by 2% agarose gel electrophore-
sis.
Nuclease-associated toxicity
Survival of HEK293T cells was assayed by measuring the
decrease of mCherry-positive cells from day 2 to day 5, nor-
malized to cells transfected with a non-functional nucle-
ase expression vector as previously described (36). Cell cy-
cle progression analysis in HeLa FUCCI was performed by
seeding 100 000 cells 24 h prior PEI transfection with 1.6
g of each nuclease monomer expression plasmid and 1.8
g of pUC118. The fractions of cells in the respective cell
cycle phase were determined by flow cytometry (FACSCal-
ibur; BD Biosciences) 3 days post-transfection. Apoptosis
was measured by staining HeLa FUCCI cells with an Al-
lophycocyanin (APC)-conjugated AnnexinV antibody (BD
Biosciences) according to the manufacturer’s protocol 1 day
post-transfection. 100 000 HEK293T cells were transfected
as described above with increasing amounts (100–600 ng) of
each nuclease monomer expression plasmid and stained for
AnnexinV 3 days post-transfection. 100 ng of a mCherry ex-
pression vector was included to normalize for transfection
efficiency and pUC118 up to 1.2 g was added in each sam-
ple. Cell viability was measured by staining HEK293T with
7-aminoactinomycin D (7-AAD) 1 day post-transfection
with nuclease expression vectors to allow the identification
of dead cells by flow cytometry.
Genomic rearrangements
Genomic DNA was extracted from HEK293T cells treated
with ZFNs or TALENs using QIAamp DNA mini kit (Qia-
gen) and was subjected to PCR amplification using the diag-
nostic primers #1474 and #986 to detect deletions (ampli-
con length 477 bp) or #1474 and #985 to detect inversions
(520 bp). PCR amplicons were resolved by 2% agarose gel
electrophoresis. The percentage of Del/Inv as shown in Fig-
ure 5C was calculated as follows: the band intensities were
estimated using Quantity One v.4.6.9 software (Biorad) and
the amount of Del/Inv (middle band) was computed as per-
centage of total CCR5 and CCR2 alleles (upper and lower
bands).
Off-target analysis
Potential off-target sites for the TALENs were chosen from
the PROGNOS RVD-5TC and Homology-5TC rankings
to contain a mixture of the top-ranked sites from both al-
gorithms. In addition, CCR2 was also interrogated for the
TC-NC TALENs to facilitate comparison at that off-target
site, even though this site did not appear in the 5TC PROG-
NOS rankings because of the lack of the 5′ pyrimidine in
one of the half-sites. The different PROGNOS ranking al-
gorithms employ various models of nuclease-DNA bind-
ing and cleavage preferences, including RVD association
frequencies (42), the energy compensation model of cleav-
age (27) and the preference of ZFNs for guanosine residues
(43). Genomic DNA was extracted from HEK293 cells 3
days post-transfection with ZFNC, ZFNA, TC06, TC-NC,
TA04 or empty vector, as described above. PCR primers de-
signed by PROGNOS (Supplementary Table S7) were used
to amplify the predicted off-target loci and amplicons were
sequenced using the RS SMRT technology (Pacific Bio-
sciences). The results were analyzed by custom Perl scripts
to identify reads containing evidence of NHEJ. The ‘speci-
ficity factor’ in Tables 1 and 2 is calculated as the ratio of
on-target to off-target mutagenesis frequency based on the
detected indels events shown in Supplementary Table S5.
Statistical analysis
Statistical differences reported in the nuclease-associated
toxicity experiments represent the average of three inde-
pendent experiments. Error bars indicate standard error of
mean (S.E.M.). Statistical significance was determined us-
ing a two-tailed, homoscedastic Student’s t-test. For off-
target site analysis, the p-values were calculated for the one-
sided alternative hypothesis that the modification frequency
at the analyzed site (insertion/deletion) is greater for the nu-
clease treated cells compared to cells transfected with the
empty vector.
RESULTS
Generation of highly active TALENs targeted to three human
genes
We generated three sets of TALEN pairs targeted to the
human loci AAVS1, CCR5 and IL2RG, for which effec-
tive benchmark ZFNs are available (18,21,24). To this
end, TALE DNA binding domains assembled with the
‘Golden Gate’ platform (39) were cloned in a TALEN ex-
pression plasmid containing an optimal architecture previ-
ously characterized in our lab (Scaffold A4-NH; (36)) (Sup-
plementary Figure S1). A total of six nuclease monomers
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Table 1. Off-target sites of CCR5-specific designer nucleases
1Nucleotide sequence differences as compared to the CCR5 target site are indicated by lower-case letters.
2Sites with statistically significant enrichment of mutated sequences (p < 0.05) are highlighted by gray background.
3For this site the PCR amplification step was not successful.
4Ratio of the total on- to off-target modification frequencies.
Table 2. Off-target sites of AAVS1-specific designer nucleases
1Nucleotide sequence differences as compared to the AAVS1 target site are indicated by lower-case letters.
2Sites with statistically significant enrichment of mutated sequences (p < 0.05) are highlighted by gray background.
3Ratio of the total on- to off-target modification frequencies.
targeted to AAVS1, seven monomers targeting CCR5 and
eight monomers targeting IL2RG were produced and ex-
pressed at similar levels (Supplementary Figure S2). Dif-
ferential pairing of these TALEN monomers allowed us
to reconfirm the optimal spacer length of 12–15 bp be-
tween the TALEN target half-sites by analyzing the activ-
ity of 34 TALEN pairs termed TC#, TA# or TI#, target-
ing CCR5, AAVS1 or IL2RG, respectively (Figure 1A and
B, Supplementary Table S1). In addition, previously val-
idated TALENs targeted to CCR5 (TC-NC) and IL2RG
(TI-NC) based on a scaffold that includes a longer linker
(+47 residues) were used as controls (36). Designer nucle-
ase activity was assessed by measuring the extent of NHEJ-
mediated mutagenic repair at the three target loci using the
mismatch-sensitive T7 endonuclease 1 (T7E1) assay (Fig-
ure 1A). When tested in cultured cells, 19 out of 36 dif-
ferent TALEN pairs showed substantial activity, resulting
in >5% of mutated target alleles. Considering only target
sites with optimal spacers of 12–15 bp or 20–22 bp lengths,
respectively, the success rate of producing active TALEN
pairs ranged from 33% for the IL2RG locus to up to 90%
and 100% for the CCR5 and AAVS1 loci, respectively. No-
tably, for all three loci we were able to identify at least one
TALEN pair that performed similarly well as the respective
benchmark ZFN, confirming the robustness of the chosen
TALEN scaffold. Furthermore, our data show that 2 out of
20 TALEN monomers analyzed (L-169 and R-170) proba-
bly failed to bind to their respective target sites because they
did not support cleavage in any of the tested nuclease con-
figurations (Figure 1A). Thus, the success rate of generating
functional monomers was ∼90%.
Assessment of the nucleotide composition of the 20
TALEN target half-sites (Figure 1C and Supplementary
Figure S3) revealed that TALENs efficiently disrupted
pyrimidine-rich target sites (AAVS1) as well as targets with-
out any prevalence of certain nucleotides (CCR5). However,
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Figure 1. Assessment of TALEN activity at three human loci. (A) Disruption of target loci. HEK293T cells were transfected with expression plasmids
encoding the indicated nuclease pair. Genomic DNA was extracted 3 days after transfection and subjected to PCR amplification of the target site followed
by T7E1 assay. The spacer lengths between each nuclease half-site and the extent of cleavage (average percentage of modified alleles) are indicated below
each panel. Arrows indicate the position of the expected cleavage products. The most active TALEN pairs are highlighted in bold. (B) Relation between
spacer and TALEN activity. The plot shows the relationship between activity and the length of the DNA spacers separating the two TALEN half-sites.
Each gray dot represents the average of three independent cleavage experiments (as shown in panel (A)), while the black dots embody the average values
of all gray dots for a particular spacer length. A trend line connects the black dots. (C) Target site nucleotide composition. The histogram indicates the
percentage of purines or pyrimidines in the target sites.
only two out of seven IL2RG-specific TALEN pairs, which
fulfilled the spacer requirements, showed robust cleavage ac-
tivity. The low targeting efficiency at this locus cannot be
explained by the nucleotide sequence of the respective tar-
gets as the target site compositions in IL2RG are similar to
those in CCR5. To explain the low success rate in generating
functional TALEN pairs targeted to IL2RG, we assayed nu-
clease activity in various cell lines that revealed differential
transcriptional activity of the target loci, as measured by
semi-quantitative RT-PCR (Supplementary Figure S4A).
Although CCR5 was not expressed in HEK293T cells, it
could be targeted with similar efficiencies as the ubiqui-
tously expressed AAVS1 locus (Figure 1A). Vice versa, we
could not detect any improvement in TALEN activity at the
IL2RG locus in K562 cells, in which IL2RG is expressed as
opposed to HEK293T cells (Supplementary Figure S4B).
These results suggest that the spacer length represents a
major determinant for TALEN activity and that gene dis-
ruption efficiency seems not to be appreciably dependent
on the transcriptional status of the target locus. However,
the presence of CpG dinucleotides in TALEN target sites
may negatively impact on the overall efficacy of TALEN
monomers to bind to their intended targets, as shown re-
cently (33,44,45). The majority of the IL2RG-specific ‘left’
TALEN monomers generated in this study are targeted to
DNA sequences containing two or three CpG dinucleotides
(Supplementary Table S1), which may explain the low suc-
cess in generating functional IL2RG-specific TALENs. In-
deed, the sole highly active IL2RG-specific TALEN pair
consists of TALEN monomers targeted to CpG-free DNA
sequences (Figure 1A and Supplementary Table S1; see nu-
clease pair TI14).
We next evaluated whether ZFNs and TALENs perform
similarly well in a primary human cell type. Gene disruption
frequencies of the most active TALEN pairs (TC06, TA04
and TI14) and our benchmark ZFNs were analyzed in pri-
mary human NuFFs. At all three loci, TALENs were simi-
larly efficacious as the ZFNs, with allelic mutation frequen-
cies ranging from 6% to 17% (Figure 2). The lower overall
activity as compared to cell lines may be due to the lower
transfection efficiency. However, the gene disruption activ-
ities of all nucleases were increased when cells were tran-
siently incubated under hypothermic conditions (46).
To further characterize the two designer nuclease plat-
forms, we profiled the kinetics of expression and activity of
our CCR5-specific TALENs and ZFNs in HEK293T cells.
The T7E1 assay revealed a comparable kinetics of activ-
ity for both platforms, with a plateau reached about 24 h
post-transfection (Figure 3A). In terms of expression, the
TALEN levels increased up to 48 h post-transfection while
ZFNs reached a peak of expression 15 h after transfection
(Figure 3B), which can be attributed to differences in pro-
tein stability and/or ZFN-associated cytotoxicity.
Nuclease-associated cytotoxicity
Based on the findings that both nuclease activity and ex-
pression peak within 48 h after transfection, we assessed
general cytotoxicity by measuring cell survival 5 days post-
transfection. All tested TALENs outperformed ZFNs with
an average of ∼80% of surviving cells expressing TAL-
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Figure 2. Designer nuclease activity in primary cells under normothermic
and hypothermic conditions. Disruption of three different target loci was
assayed in primary newborn human foreskin fibroblasts. Upon nucleofec-
tion with plasmids expressing the respective ZFNs or TALENs (TC06 for
CCR5, TA04 for AAVS1 and TI14 for IL2RG), cells were incubated at
37◦C or 30◦C for 3 days. Genomic DNA was extracted and the target
sites amplified by PCR prior to digestion with T7E1. The arrows indicate
the positions of the expected digestion products. The average percentage
of modified alleles is indicated below each panel. m, mock; Z, ZFN; T,
TALEN.
ENs versus ∼50% for ZFN-expressing cells (Figure 4A). To
study this effect in more detail, we investigated the impact
of nuclease expression on cell cycle progression. We rea-
soned that nuclease-associated toxicity is probably caused
by cleavage at off-target sites, which in turn arrests the cell
cycle until the DSBs are repaired. To this end, we expressed
the most active CCR5-specific TALEN TC06 and ZFNC
in HeLa FUCCI cells that express fluorescently tagged cell
cycle indicators (47). Flow cytometric cell cycle analysis af-
ter 1 and 3 days revealed that cells expressing TALENs
were not different from control samples, while ZFN ex-
pression induced a significant accumulation of cells in G1
phase 1 day post-transfection followed by an accumulation
in S-G2-M phase 3 days after transfection (Figure 4B). In
agreement, the transient cell cycle deregulation was asso-
ciated with a significant increase in apoptotic cells (Figure
4C), suggesting that a significant subset of cells was not
able to repair the nuclease-induced DSBs, which in turn in-
duced cell death. To correlate induction of apoptosis with
nuclease expression, we transfected HEK293T cells with in-
creasing amounts of CCR5-specific nuclease expression vec-
Figure 3. Kinetics of ZFN and TALEN expression and activity.
HEK293T cells were transfected with the indicated CCR5-specific nuclease
pairs and harvested at different time points after treatment. (A) Kinetics of
nuclease activity. Target locus disruption was assayed by T7E1 assay and
the extent of cleavage (as percentage of modified alleles) is indicated below
each lane. (B) Kinetics of nuclease expression. Expression levels were de-
termined by immunoblotting using antibodies against HA-tag (top panel)
and -actin (lower panel). Positions of TALENs, ZFNs and -actin are
indicated on the right and protein marker (in kDa) on the left.
tors. Augmenting the ZFNC load resulted in higher num-
bers of AnnexinV-positive cells (Figure 4D and Supplemen-
tary Figure S5). At medium and high concentrations, only
the CCR5-specific ZFNs––but not TALENs TC06 and TC-
NC––induced a significant level of apoptosis above back-
ground levels (note that experiments in Figure 4A and B
have been performed using 400 ng of each nuclease plas-
mid and that TALEN and ZFN plasmids have a compa-
rable size). Cells transfected with a previously described
toxic ZFN pair (40) showed marked apoptosis in up to 32%
of the total cell population (Supplementary Figure S5A).
To further inspect nuclease-associated toxicity, we stained
HEK293T cells with 7-AAD 2 days post-transfection with
expression vectors encoding the most active nuclease for
each of the three loci. This chemical compound intercalates
in the DNA double helix with high affinity. However, since
7-AAD cannot penetrate an intact cell membrane, it is used
to effectively discriminate between live and dead cells. While
samples expressing TALENs did not show any difference
compared to control samples, expression of ZFNs targeted
to CCR5 and IL2RG led to a significant increase in 7-AAD
positive cells (Figure 4E). In summary, expression of TAL-
ENs was well tolerated by human cells.
Specificity of designer nucleases targeted to CCR5 and
AAVS1 loci
As the CCR5-specific ZFNs are the only designer nucle-
ase pair in clinical trials, they are the best-characterized
nucleases in terms of specificity to date (26,27). On the
other hand, AAVS1-specific ZFNs are broadly used in the
genome engineering field because the locus is considered a
‘safe harbor’ (48) but only few specificity data are available
6768 Nucleic Acids Research, 2014, Vol. 42, No. 10
Figure 4. Nuclease-associated toxicity. (A) Cell survival. HEK293T cells were co-transfected with plasmids encoding the most active TALENs or ZFNs
for the three loci tested together with a mCherry expression plasmid. The graph shows the fraction of mCherry-positive cells at day 5 as compared to day 2
post-transfection, relative to samples transfected with a control plasmid. (B) Cell cycle analysis. HeLa FUCCI cells were transfected to express the indicated
nucleases and cell cycle progression was monitored by flow cytometry one (upper panel) and three (lower panel) days post-transfection. The graph shows
the average percentage of cells in the respective cell cycle phase. (C and D) Nuclease-associated apoptosis. Apoptotic response to nuclease treatment was
monitored by AnnexinV staining in HeLa FUCCI cells (C) or in HEK293T cells (D) transfected with increasing amounts of nuclease expression plasmids.
The gray shaded areas indicate transfection-associated apoptosis. (E) Cell viability. HEK293T cells were transfected with expression vectors encoding the
most active TALEN or ZFN pairs. The diagram shows the fraction of 7-AAD positive cells 1 day post-transfection. Statistically significant differences
between ZFNs and controls or ZFNs and TALENs are indicated with an asterisk and the corresponding p-values (two-tailed, Student’s t-test). Error bars
indicate S.E.M.
for this ZFN (21). We therefore profiled off-target activity of
our CCR5- and AAVS1-specific ZFNs and TALENs. First,
we investigated the activity of the CCR5-specific nucleases
at the CCR2 locus that has been reported to be a prominent
off-target site of CCR5-specific ZFNs (26,27,49). CCR2
is located about 15 kb upstream of the CCR5 locus on
chromosome 3 and its coding sequence is highly similar to
CCR5. Within a 60-bp stretch that surrounds the identified
ZFN off-target site in CCR2, only five nucleotides are dif-
ferent from the corresponding stretch in the CCR5 locus
(Supplementary Table S2). Gene disruption at the CCR2
locus was evaluated for the entire panel of CCR5-specific
TALEN pairs and the benchmark ZFN by the T7E1 assay
in HEK293T cells (Figure 5A). While ZFNC showed con-
siderable activity at CCR2, some of the CCR5-specific TAL-
ENs revealed little or no off-target activity at this locus. Im-
portantly, TALEN pair TC-NC showed high on-target mu-
tagenic activity at CCR5 but undetectable off-target cleav-
age at CCR2, demonstrating that rational design may allow
for the generation of TALEN pairs that can discriminate
between highly identical targets in the human genome.
A potential deleterious effect driven by the generation
of two simultaneous DSBs in a genome is the induction of
genomic rearrangements. To investigate whether concomi-
tant cleavage at CCR5 and CCR2 induces deletions or in-
version of large genomic fragments on chromosome 3, as
previously shown (49,50), we genotyped a subset of sam-
ples transfected with CCR5-specific nucleases by qualita-
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tive PCR (Figure 5B). We monitored deletions as well as
inversions occurring between CCR2 and CCR5 in sam-
ples treated with the ZFN pair and TALENs TC06 and
TC12 that were unable to discriminate between the two
loci (Figure 5C). However, chromosomal rearrangements
were not detected in samples treated with TALEN pairs
active only at CCR5 (TC09, TC10, TC-NC). To estimate
the extent of rearranged alleles in the transfected cell pop-
ulation, we mixed the four diagnostic primers in a single
PCR reaction and computed the frequency of deletions or
inversions (Del/Inv) for the non-discriminating nucleases
(ZFNC, TC06, TC12) to be in the range of about 15% of the
total number of alleles. The TALEN pair TC-NC did not
induce detectable levels of genomic rearrangement between
the two loci, emphasizing the importance of minimizing off-
target cleavage, in particular on the same chromosome.
We next investigated the specificity of our CCR5- and
AAVS1-specific designer nucleases by high-throughput se-
quencing at potential off-target sites predicted in silico us-
ing the recently developed PROGNOS software (http://
bit.ly/PROGNOS). When applying the bioinformatics tool,
four of seven previously validated off-target sites (Table 1;
(26,27)) were listed in the top 32 off-target sites for the
CCR5-specific ZFN (Supplementary Table S3). For the
AAVS1-specific ZFN, few specificity data are available in
the literature. PROGNOS confirmed the prediction of two
out of five previously identified but not validated (21) off-
target sites in the top 23 list of predicted off-target sites
(Supplementary Table S3). We also used PROGNOS to pre-
dict the top 15 off-target sites for TC06 and TC-NC, respec-
tively, and the top 22 off-target sites for the AAVS1-specific
TALEN TA04.
For the CCR5-specific ZFN, we confined high-
throughput sequencing analysis to those sites that were
previously identified and we confirmed off-target cleavage
activity at six out of seven sites analyzed, sometimes with
disruption activities over 12%, i.e. almost as high as at the
CCR5 locus. Moreover, PROGNOS was able to predict a
novel off-target site on chromosome 5 (51). Analysis of off-
target cleavage of the AAVS1-specific ZFN pair revealed
activity of up to 4.4% at 5 out of the 23 predicted off-target
sites (Table 2 and Supplementary Table S5). Hence, we
validated three previously predicted off-target sites and
identified and validated two additional off-target sites for
the AAVS1-specific ZFN. In addition to CCR2, the two
CCR5-specific TALEN pairs exhibited minor off-target
cleavage activity (0.12%) at a total of three off-target sites.
The AAVS1-specific TALEN pair revealed statistically
significant activity at 1 (0.13%) out of the 22 predicted
off-target sites (Table 2 and Supplementary Table S5).
The majority of mutations retrieved at the analyzed
loci consisted of short deletions in the respective spacer
sequences, as previously reported (52), and DNA repair
seemed to be driven mostly by microhomology-mediated re-
pair (Supplementary Table S6 and data not shown).
In summary, the high-throughput sequencing results ex-
posed important information regarding the specificity of the
assessed nucleases. In particular, compared to the bench-
mark ZFN, our CCR5-specific TALENs are better toler-
ated when expressed in human cells and can be designed
to discriminate between highly identical sequences, such as
CCR5 and CCR2. The CCR5:CCR2 targeting ratio was de-
termined to be in the range of 3:1 for the ZFN, and 130:1
or 7:1 for the TALEN pairs TC-NC and TC06, respectively.
The calculated ‘specificity factor’, indicating the ratio of the
frequency of on-target mutagenesis to the overall frequency
of off-target mutagenesis, was 1:2 for the CCR5-specific
ZFN, 60:1 for TALEN TC-NC and 7:1 for TALEN TC06
(Table 1). A similar trend was observed for the AAVS1-
specific nucleases. While we identified and validated five
novel off-target sites for the AAVS1-specific benchmark
ZFN, with a specificity factor of 1:2, we detected off-target
cleavage activity at a single predicted site for TALEN TA04,
with a calculated specificity factor of 27:1 (Table 2).
DISCUSSION
Targeted genome editing with engineered nucleases has
been successfully applied in various organisms and cell
types (1,3,15). However, a study that correlates activity, cy-
totoxicity and specificity highlighting advantages and limi-
tations associated with the use of the various nuclease plat-
forms is still lacking. Here we provide the first thorough
characterization of a panel of designer TALENs targeted
to three human genes for which effective benchmark ZFNs
are available (18,21,24). We identified TALENs that show
activity comparable to the matching ZFNs both in human
cell lines and in primary human fibroblasts. Assessment of
nuclease-associated toxicity in human cells revealed that
overexpression of TALENs is better tolerated than that of
benchmark ZFNs. Moreover, profiling nuclease specificity
in HEK293T confirmed off-target activity of the CCR5-
specific ZFNs and provides the first data for the AAVS1-
specific ZFN pair with five novel off-target sites identi-
fied. In contrast, the best performing CCR5- and AAVS1-
specific TALEN pairs showed only negligible activity at a
total of 49 off-target sites analyzed.
Using our optimized TALEN scaffold that includes a 17
residue linker (+17aa) between the last TALE repeat and the
FokI endonuclease domain (36), we were able to generate ef-
fective nucleases able to induce modifications in up to 30%
of alleles at three human loci, which was similarly high as
the benchmark ZFNs. In line with previous reports (13,14),
we achieved a high success rate in generating functional
TALEN monomers, regardless of the nucleotide composi-
tion of the target sequence and without respecting any pre-
viously published design guidelines. Furthermore, we cor-
roborate that our TALEN scaffold with a short +17 residue
linker works optimally on DNA spacers of 10–15 bp, with a
second peak of activity on 20–22 bp long spacers. This sec-
ond peak of activity is consistent with formation of an ac-
tive TALEN complex spaced to include an additional DNA
helix turn, and in line with observations previously made
for ZFNs (53,54). Most of the 16 non-functional TALEN
pairs tested hence failed to cleave the target DNA because
the spacer length requirements were not fulfilled. Consider-
ing only target sites with optimal spacer lengths, the success
rate of producing active TALEN pairs ranged from 33% for
the IL2RG locus to 90% for the CCR5 locus and 100% for
the AAVS1 locus.
The impact of the chromatin structure and/or the epi-
genetic status of a locus on nuclease activity is still poorly
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Figure 5. Nuclease-associated genotoxicity. (A) Off-target activity of CCR5-specific nucleases. The activity of the indicated nucleases at the human locus
CCR2 was monitored by T7E1. The spacer between the target half-sites and the average extent of cleavage at both CCR5 and CCR2 loci are indicated
below. Arrow indicates the position of the expected digestion products. (B) Schematic of chromosomal organization of the CCR2 and CCR5 loci. The
predicted genomic rearrangements that can occur upon simultaneous cleavage in both loci are shown: deletion (left panel) or inversion (right panel).
Capital letters indicate positions of the primers used for molecular characterization. (C) Genomic rearrangements upon expression of designer nucleases.
Genomic rearrangements were detected by PCR using the indicated primer pairs: A+D, deletion (Del, 477 bp, top); A+C, inversion (Inv, 520 bp, middle);
A+B, CCR2 allele (674 bp, bottom); C+D, CCR5 allele (300 bp, bottom). Nuclease specificities and estimated percentage of Del/Inv products are indicated
on the bottom. DNA-marker (in bp) is shown on the right.
understood. The low success frequency at IL2RG could
therefore be attributed to chromatin structure and/or DNA
methylation that may negatively affect accessibility or DNA
binding affinity of the TALENs (33). Our results suggest
that the transcriptional status of a locus is not a major de-
terminant of TALEN activity. Interestingly however, the
presence of CpG dinucleotides within the target sequences
seems to substantially affect TALEN activity. While all
the CCR5- and AAVS1-specifc TALENs and the only
highly active IL2RG-specific TALEN pair identified in this
study bind to CpG-free DNA target sequences, the non-
functional IL2RG-specific TALEN pairs contain two or
three CpG dinucleotides in the left target subsite. A more
systematic approach is needed to address this point. In line
with a recent report in zebrafish (33) and with previously
published data showing that the HD module is not able
to bind to 5mC (45), our data emphasize that CpG dinu-
cleotides should be avoided when searching for amenable
TALEN target sites in the human genome. Intriguingly, ac-
tivity of the IL2RG-specific ZFN pair was not affected by
the presence of two CpG dinucleotides in the left target sub-
site. This observation raises important considerations re-
lated to the TALEN platform. The reduced activity of TAL-
ENs at sites containing CpG dinucleotides may decrease
the potential target range in the human genome on the one
hand (unless modules that allow binding to 5mC are used)
but, on the other hand, increases specificity as potential off-
target sites in methylated genome regions cannot be cleaved.
Nuclease specificity is a key factor for advancing tar-
geted genome engineering into the clinic. Here we show
that expression of TALENs is generally well tolerated by
human cells. In contrast, expression of our ZFN pairs
reduced cell survival, was associated with cell cycle ar-
rest and increased cell death, all of which suggest surplus
DNA cleavage at off-target sites. Using the newly developed
PROGNOS bioinformatics tool (51), we predicted poten-
tial ZFN and TALEN off-target sites in the human genome
and screened them by high-throughput sequencing. Impor-
tantly, the top 32 ranked potential off-target sites of the
CCR5-specific ZFN included four off-target sites in the top
seven that were previously verified experimentally (26,27)
and one novel site (51). The top 23 predicted off-target sites
for the AAVS1-specific ZFN included two previously pre-
dicted sites and allowed us to verify a total of five novel
off-target sites. PROGNOS was also successfully employed
to predict four novel off-target sites for TALENs targeting
beta-globin (51). These results clearly validate and under-
line the high predictive value of PROGNOS that can be re-
liably applied to predict both ZFN and TALEN off-target
sites.
In our study we have profiled TALEN off-target activ-
ity in a non-clonal cell population with high-throughput
sequencing. Many previous reports have either focused
on identifying the integration site of non-integrating vi-
ral vectors trapped in TALEN-induced DSBs (38) or using
Surveyor/T7E1 assays to monitor off-target activity at ge-
nomic loci predicted by bioinformatics (55). However, the
small number of off-target sites identified and analyzed or
the use of genomic DNA extracted from clonally derived
cell populations or live animals (56,57) may likely not pro-
vide enough depth to identify rare mutagenic events at off-
target sites as those identified here. The five novel off-target
sites of the widely used AAVS1-specific ZFN are certainly
of importance to those researchers currently using or plan-
ning to use this nuclease pair for targeted integration at
the AAVS1 ‘safe harbor’ locus. Given the superior toxic-
ity profile and the absence of significant off-target activity,
our AAVS1-specific TALEN pair TA04 might be a valid al-
ternative for targeted gene addition into the AAVS1 ‘safe
harbor’ site, in particular in primary cells.
Due to the high sequence similarity with CCR5, assess-
ment of nuclease specificity confirmed that the major off-
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target sites of our CCR5-specific ZFN and TALEN pairs
were found in the CCR2 locus. As reported before, con-
comitant cleavage at CCR2 and CCR5 results in deletion
of the intervening sequence (30,49). We show that nucle-
ases, which are not specific enough to discriminate between
these two highly similar loci (i.e. ZFNC and TC06), in-
duce deleterious genomic rearrangements, including dele-
tions and inversions. Even though not investigated further,
we envision that simultaneous off-target activity on two
different chromosomes can induce translocations between
two major off-target sites, as previously shown (58). Im-
portantly, we show that such deleterious genotoxic events
can be restrained by using rationally designed nucleases,
such as TALEN TC-NC, which shows an unprecedented
CCR5:CCR2 targeting ratio of ∼130:1. We speculate that
the ability of TALEN TC-NC in discriminating between
CCR5 and CCR2 is based on the fact that one of the two
TC-NC subunits targets a T in position 0, which is not
present in CCR2. Thus, the 5′-T can be used as a major
discriminant between highly similar off-target sites to over-
come cytotoxic side effects.
Examination of the few off-target sites shows that TAL-
ENs tolerate up to five mismatches in their 19-bp target
half-sites. Whether the position of these mismatches has an
impact on the overall binding affinity of TALEN monomers
has not been addressed here. In any case, a systematic anal-
ysis of TALEN off-target activity may provide novel design
guidelines that can be taken into consideration in the fu-
ture to avoid potential off-target activity at sites with more
than 74% nucleotide identity to the intended target site.
Our sequencing data revealed some few off-target muta-
genic events at predicted homodimeric TALEN off-target
sites for our CCR5-specific TALENs. Thus, TALEN speci-
ficity can be further increased by coupling the TALE DNA
binding domains to obligate heterodimeric FokI endonucle-
ase variants (59,60) that have been shown to abolish cleav-
age of ZFNs at homodimeric off-target sites (26). Even
though most of our findings are based on TALENs with
the 135/+17 scaffold developed in our lab (36), we believe
that they can be extended to alternative TALEN designs
with longer linkers (61). Importantly, as shown for ZFNs
(53), our short 17-residue linker may improve specificity by
limiting spacer tolerability. Additionally, intranuclear con-
centration of the designer nucleases and duration of the ex-
pression are important parameters affecting cleavage speci-
ficity. For instance, delivery of a CCR5-specific ZFN pair
in the form of proteins resulted in short persistence in the
transduced cells and was associated with reduced off-target
activity at CCR2 (62).
We systematically measured higher off-target activity of
the CCR5-specific ZFNs than previously published (26,27).
We reason that this is most likely due to the cell line
(HEK293T versus K562 cells) and the transfection method
(PEI versus nucleofection) that we used, which may result
in higher intranuclear nuclease expression levels. Also, our
ZFNs contain a slightly different obligate heterodimeric
FokI domain (41) compared to the most commonly used
one (63) and a different epitope tag (HA versus FLAG).
Given that we were able to identify previously reported off-
target sites at much higher frequencies demonstrates that
PEI-mediated transfection of HEK293T cells represents an
ideal ‘mutation-prone system’ to evaluate nuclease speci-
ficity and further emphasizes the high specificity of the
TALENs tested here.
Taken together, our results establish TALENs as a safe
and specific platform to edit the human genome, paving the
way for their use for clinical translation. As mentioned pre-
viously, RGNs have been established as a versatile tool to
modify the human genome (15). Although there has been
some concern regarding their specificity (28–30), it will be
interesting to see whether this novel class of designer nucle-
ases can match the high specificity set by TALENs, e.g. as
recently shown by truncating the gRNA molecule (64).
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